fbpx
COVID-19 India Update

COVID-19 India Update

India Coronavirus Update: Death Rate 3.3% Recovery Rate 12.02%

Indian Health Ministry notes the death rate at 3.3% with an 11.2% recovery rate.A total of 3,02,956 samples from 2,86,714 individuals have been tested as of Thursday.

  • Active/Confirmed Cases: 12,759
  • Deaths: 420
  • Recovered (Cured and Discharged): 1541
  • Cases per 1 million people:9.3


Indian Health Ministry notes the death rate at 3.3% with an 11.2% recovery rate. The Indian Council of Medical Research (ICMR) said that the rapid testing kits are not for diagnosis but for surveillance, mostly in hotspots.

A total of 3,02,956 samples from 2,86,714 individuals have been tested as of Thursday.


Are we testing less?

COVID-19 Status Update India
Image Source: www.thehindu.com

ICMR spokesperson R.R. Gangakhedkar ~ “Working in one shift, more than 42,400 samples can be tested per day; if we work in two shifts, we will be able to test more than 78,200 samples per day,”

ICMR says that we are not testing less, According to ICMR

  • India tests 24 people for one positive test which is more than other countries.
  • Japan tests 11.7 people for one positive case
  • Italy tests 6.7 people for one positive case
  • The US tests 5.3 people for one positive case

India has received 5 Lakh rapid COVID-19 test kits from China on 16th April,5.5 lakh Rapid Antibody Testing Kits and 1 lakh RNA Extraction Kits were part of the consignment.

ICMR spokesperson R.R. Gangakhedkar ~ “These have a sensitivity of over 80% and are serology kits which is not to be used for early diagnosis but for surveillance purpose, especially in hotspots,”

Regarding the effectiveness of the antibody testing kit He further

If an antibody test of a person turns out to be positive, one cannot necessarily be sure the person would not get infected ever again. This means, even if antibodies are present, that doesn’t mean it will necessarily be effectively able to fight the virus.”


“Rapid antibody tests are for monitoring surveillance, not for diagnosis. Hence there is no concern with respect to the testing kits being faulty, that concern was with respect to immune response alone”

The Central government said that they have amended the Environment Impact Assessment Notification, 2006, to boost the availability and production of bulk drugs. All activities or projects in relation to bulk drugs have been re-categorized, to speed up their assessment.

Leave a Reply

Your email address will not be published. Required fields are marked *